We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current EX1 market cap is 4.83M. The company's latest EPS is AUD -0.0162 and P/E is -0.62.
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 2.67M | 4.19M | 4.21M | 3.39M |
| Operating Income | -2.31M | -5.34M | -8.48M | -10.01M | -6.82M |
| Net Income | -2.28M | -5.28M | -8.47M | -10.08M | -7.13M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 5.4M | 6.54M | 21.46M | 13.61M | 5.88M |
| Total Liabilities | 281k | 1.53M | 2.59M | 4.81M | 1.75M |
| Total Equity | 5.12M | 5.02M | 18.87M | 8.81M | 4.13M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -2.19M | -6.7M | -7.83M | -8.53M | -3.85M |
| Investing | -859k | -950k | -1.8M | -1.24M | -277k |
| Financing | 7.41M | 4.97M | 20.61M | 1.88M | 919k |
| Market Cap | 4.83M |
| Price to Earnings Ratio | -0.62 |
| Price to Sales Ratio | 1.3 |
| Price to Cash Ratio | 2.7 |
| Price to Book Ratio | 1.06 |
| Dividend Yield | - |
| Shares Outstanding | 439.42M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 37.50% |
| 52 Week High | 0.016 |
| 52 Week Low | 0.008 |
| Spread (Intraday) | 0 (9.09%) |
| Company Name | Exopharm Limited |
| Address |
suite 201 melbourne, victoria |
| Website | https://tryptherapeutics.com/ |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
